Shots:

• The P-I trial assessed safety & PK/PD (free IgE levels) of LP-003 in healthy individuals (n=32) divided into 5 arms to administer single IV dosing (0.3mg/kg, 1mg/kg, 3mg/kg, 6mg/kg & 10 mg/kg)
• The study depicted LP-003’s non-linear PK profile with a half-life of 44.6 to 76.5 days which was ~2-3 times that of omalizumab with a free-IgE suppression in the 1mg/kg (except for one participant with a high baseline IgE level) to 10mg/kg groups below the detection range for >168 days
• The company is recruiting refractory CSU patients (n=200), symptomatic after anti-histamine (H1) treatment, for P-II study who will be divided into 5 arms (n=40/arm) incl. 3 LP-003 arms, 1 omalizumab arm & 1 PBO arm. Topline data is expected in early 2025

Ref: PR Newswire | Image: Longbio Pharma

Related News:- Sanofi Highlights Results from the P-II Trial of Rilzabrutinib for the Treatement of Chronic Spontaneous Urticaria (CSU) at AAAAI 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com